LifeScan Study Proves Noom’s Impact on Diabetes Management

Now more than ever, there’s a need for more support for people with type 2 diabetes. 

Unmanaged diabetes isn’t just costing people a healthy lifestyle – the U.S. healthcare system and its employers are paying a significant price, too. The total direct estimated medical costs of diagnosed diabetes increased from $227 billion in 2012 to $307 billion in 2022.¹

That’s why LifeScan, a manufacturer of diabetes-related products and services, sought to find out how widely available tools such as digital health apps can play a key role in improving health outcomes for those with type 2 diabetes.

The 2025 ECLIPSE study evaluated combining Bluetooth connected OneTouch blood glucose meters and the OneTouch Reveal mobile app with one of four digital therapeutic apps, including Noom, to improve glycemic outcomes. 

Subjects who chose to use Noom in the ECLIPSE study synced their Bluetooth connected OneTouch blood glucose meter to the OneTouch Reveal (OTR) diabetes management app. Subjects then connected their OTR app to their Noom app to allow blood glucose readings to appear within the Noom application.

Those who participated in the study were 18 years or older and living in the U.S. with a self-reported diagnosis of type 2 diabetes, had a current A1c value of ≥ 7.5 and ≤ 12.0%, a body mass index ≥ 27 (based on self-reported height and weight), and self-reported use of at least one oral and/or injectable diabetes medication.

After three months, the study revealed that Noom Diabetes Support, an early version of Noom’s Diabetes Management program, effectively helped people lower their A1c levels.²

Noom’s proven behavior change reduces A1c

Rooted in Noom’s evidence-based behavior change foundation via cognitive behavioral therapy, Noom Diabetes Support is a comprehensive program that offers personalized coaching, clinical care, and intuitive tools and content to help members with type 2 diabetes build healthier, sustainable habits to better control their A1c and improve their long-term health. 

An analysis of 49 of the 68 subjects who chose to use Noom in the ECLIPSE study (19 did not return their A1c test kit at 3 months) showed that OneTouch paired with Noom drove a 1.03% A1c reduction from baseline after 3 months. OneTouch paired with Noom outperformed pairings with Fitbit (-.56% A1C reduction), Cecelia (-.76% A1c reduction), and Welldoc (-.55% A1c reduction). Moreover, 55% of subjects using OneTouch and Noom reduced their A1c by at least .5%.²

Moreover, 37% of the subjects using OneTouch and Noom reduced their A1c by at least 1%. An additional 24%, 22%, or 29% of subjects using OneTouch and Noom achieved HEDIS goals of an A1c < 7.0%, < 8.0, or < 9.0%, respectively, compared to baseline.²

All 68 subjects who used OneTouch and Noom saw:^.2 

• Mean blood glucose reduced by − 21.8 mg/dL
• Readings in tight range (RITR) improved by +13.7% points from 30.8 to 44.4% 
• Readings in range (RIR) increased by + 7.2% points from 66.8 to 74.0% 

High engagement plays key role in improving outcomes 

Internal data has shown that 50% of Noom’s monthly active members engage daily, putting us on par with leading social media sites.³ This high engagement was further proven in the ECLIPSE study, with 69.1% (47/68) of subjects active in the Noom app at least once weekly, including reading articles, logging meals, or weighing in. The study reports “promising weekly engagement metrics with Noom with 85% (44/52) of subjects recommending OneTouch devices combined with Noom.”² 

Results fuel real-word opportunity to transform diabetes management 

The results of the ECLIPSE study demonstrate that therapeutics aimed towards lifestyle interventions are effective at delivering better diabetes management, with the study noting the data “supports the view that engagement with relatively low cost and widely accessible digital health and wellness therapeutics can move the dial on type 2 diabetes management in a positive direction.” 

Notably, over 25% of the ECLIPSE study’s entire cohort were using an incretin medication, and 20% were using an SGLT-2 inhibitor, with high medication adherence (80% or better) self- reported by 77% of the subjects. Yet, the cohort still met the study’s inclusion criterion of an A1c 7.5% or higher, highlighting the difficulty those with type 2 diabetes have in managing diabetes and/or their weight, despite having access to newer, effective medications.²

The key takeaway for payers? Successful diabetes management interventions extend beyond medication and monitoring and include behavior change to help people build lasting healthier habits and lifestyles – not only to improve diabetes outcomes, but to also prevent the onset of additional chronic disease. 

Moreover, the approach of this study (the nature of the recruitment, assignment, and technology on-boarding processes) closely resembles how consumers and people with diabetes typically engage with digital therapeutics at home. This suggests that offering solutions that combine lifestyle and behavior change support with blood glucose monitoring in the real world – i.e. offering Noom Diabetes Support to your employees or members, can drive positive outcomes for your population and organization. 

This is your opportunity to transform how your population manages their diabetes and prevents the onset of additional chronic diseases with proven behavior change support. See for yourself how Noom can make the difference. 

References:

*https://diabetesresearch.org/diabetes-statistics/ and https://www.cdc.gov/diabetes/about/about-type-2-diabetes.html.

**https://www.cdc.gov/diabetes/php/data-research/index.html.

¹https://www.cdc.gov/diabetes/php/data-research/index.html.

²Grady, M., Holt, E., Cameron, H. et al. Improved glycemic outcomes in people with type 2 diabetes using smart blood glucose monitoring integrated with popular digital health therapeutics. Sci Rep 15, 8871 (2025). https://doi.org/10.1038/s41598-025-93605-1.

³Noom internal product data.